Cypher Genomics Acquired
HLI is creating a database of whole genome, phenotype and clinical data, which will be analyzed using machine learning and large-scale computing, and made available to customers. The firm is also working to develop cell therapy–based diagnostic and therapeutic solutions. HLI’s initial focus is cancer, building a database of patient information from the University of California, San Diego, and other partners.
San Diego, CA 11/30/15—Genomics database firm Human Longevity, Inc. (HLI) has purchased Cypher Genomics for an undisclosed amount. Cypher Genomics, which has 14 employees, develops genomic interpretation software, including the Mantis platform for interpretation of genomic sequencing data to uncover clinically significant variants and the Coral biomarker discovery service. “Cypher Genomics has created important automated and scalable genome interpretation technology informed by additional expertise in genetics and biology that we believe will be invaluable to HLI’s business,” stated HLI cofounder and CEO J. Craig Venter, PhD. “We developed Mantis and Coral to provide rapid, automated, genome interpretation at scale, enabling disease gene identification, population-based studies, diagnostic development and biomarker identification,” said Cypher CEO and cofounder Ashley Van Zeeland, PhD. Dr. Van Zeeland will serve as head of HLI’s Pediatric Business.
